These included 15 samples from 1kGP with CNVs or gene conversions, and 22 samples from Parkinson’s Progression Markers Initiative (PPMI—included in AMP-PD cohort), where Gauchian showed CNVs or GBAP1-related variants (n = 7), or was discordant with available Broad Institute’s Joint Genotyping pipeline (referred to as BWA-GATK in this paper) results (n = 4), or no mutation was reported by Gauchian or BWA-GATK (n = 11). This evidence concerns the gene GBA1LP and Parkinson disease.